Anagram Therapeutics
Last verified 2026-05-14. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $285.0Mattributed |
|---|---|
| Latest round | series-c, $250.0M, 2026-05-08attributed |
| Founded | 2017 |
| Headquarters | Natick, MA |
| Industry | biotech |
| Stage | series-b+ |
| Website | anagramtx.com |
Anagram Therapeutics develops oral enzyme replacement therapies for rare malabsorption and nutrient metabolism disorders. Its lead candidate ANG003 is in Phase 2 trials for cystic fibrosis and exocrine pancreatic insufficiency in infants, children, and adults. Proprietary enzyme stabilization technology extends activity through the GI tract where competitors degrade.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-05-08 | series-c | $250.0M | undisclosed |
Detected tech stack
Nginx, Bootstrap 5.3.2, Google Analytics, Google Tag Manager, jQuery CDN, jsDelivr, ExpressionEngine, DoubleClick Floodlight, CodeIgniter, WordPress, PHP, MySQL
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series C, $250.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Total raised $285.0M | attributed | crunchbase named as publisher. No document URL on file. |
| Company existence | self-reported | anagramtx.com, read 2026-05-14 |
| Description | self-reported | anagramtx.com, read 2026-05-14 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.